Defence Therapeutics Inc
Grey Market:DTCFFView on Canadian Exchange

  • LAST PRICE
    0.4140
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.2000/ 25
  • Ask / Lots
    0.7468/ 10
  • Open / Previous Close
    --- / 0.4140
  • Day Range
    ---
  • 52 Week Range
    0.4000
    2.1800
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 6:17PM ET on Monday Nov 04, 2024 by Dow Jones
      Companies Mentioned: DTC

      Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that it has received a 30-day extension approval from Canadian Securities Exchange to extend the closing for the balance of its previously announced non-brokered private placement of units of the Company (the "Units") at a price of $0.50 per Unit (the "Offering"). Under the first tranche of the Offering which closed on October 30, 2024, the Company sold 1,550,000 Units for gross proceeds of $775,000.

    • 6:16PM ET on Monday Nov 04, 2024 by Newsfile
      Companies Mentioned: DTCFF

      Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that it has received a 30-day extension approval from Canadian Securities Exchange to extend the closing for the balance of its previously announced non-brokered private placement of units of the Company (the "Units") at a price of $0.50 per Unit (the "Offering"). Under the first tranche of the Offering which closed on October 30, 2024, the Company sold 1,550,000 Units for gross proceeds of $775,000.

  • Oct 30, 2024

      Show headlines and story abstract

    • 6:01PM ET on Wednesday Oct 30, 2024 by Newsfile
      Companies Mentioned: DTCFF

      Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of the 1st tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of $0.50 per Unit for aggregate gross proceeds of $775,000 (the "Closing"). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one-half of one common share purchase warrant (each whole, a "Warrant"). Each Warrant is exercisable to acquire one additional Share at an exercise price of $1.00 per Share for a period of 24 months from the date of the Closing (the "Warrant Expiry Date").

    • 6:01PM ET on Wednesday Oct 30, 2024 by Dow Jones
      Companies Mentioned: DTC

      Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the closing of the 1(st) tranche of its previously announced non-brokered private placement (the "Offering") of units of the Company (the "Units") at a price of $0.50 per Unit for aggregate gross proceeds of $775,000 (the "Closing"). Each Unit consists of one common share in the capital of the Company (each, a "Share") and one-half of one common share purchase warrant (each whole, a "Warrant"). Each Warrant is exercisable to acquire one additional Share at an exercise price of $1.00 per Share for a period of 24 months from the date of the Closing (the "Warrant Expiry Date").

Peers Headlines

No documents available